Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

Close to 3 years af­ter Ver­tex helped Ar­bor Biotech­nolo­gies get off the ground with a rep­u­ta­tion-build­ing al­liance to build gene-edit­ing tools for a suite of core dis­eases, in­clud­ing cys­tic fi­bro­sis, they’ve come back to go up to $1.2 bil­lion deep­er in­to their shared jour­ney of dis­cov­ery. On­ly this time they’re col­lab­o­rat­ing on ex vi­vo en­gi­neered cell ther­a­pies.

They’ve broad­ened the sphere of their work with the biotech, go­ing af­ter type 1 di­a­betes as well as sick­le cell dis­ease and be­ta tha­lassemia — plus a few that are be­ing left off the radar for now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER